Sucampo Pharmaceuticals (SCMP) Lowered to Hold at Zacks Investment Research
Sucampo Pharmaceuticals (NASDAQ:SCMP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.
According to Zacks, “Sucampo’s pending acquisition by Mallinckrodt for $1.2 billion have raised investor concerns that the latter may be underpaying for the company. A sNDA for label expansion of Amitizia in pediatric functional constipation is under review. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. Moreover, Sucampo discontinued Amitzia’s sprinkle formulation development as it did not meet bioequivalence with capsule formulation. Shares of the company have outperformed the industry. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters.”
Several other equities analysts have also recently weighed in on SCMP. ValuEngine upgraded Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Nomura reiterated a “neutral” rating and issued a $18.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Friday, January 26th. Maxim Group downgraded shares of Sucampo Pharmaceuticals to a “hold” rating in a research report on Monday, January 1st. Mizuho reiterated a “neutral” rating and issued a $18.00 price objective (up previously from $14.00) on shares of Sucampo Pharmaceuticals in a research report on Wednesday, January 3rd. Finally, B. Riley started coverage on shares of Sucampo Pharmaceuticals in a research report on Tuesday, November 14th. They issued a “buy” rating and a $14.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Sucampo Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $20.25.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm had revenue of $61.27 million for the quarter, compared to analysts’ expectations of $58.05 million. During the same quarter last year, the business earned $0.30 earnings per share. The company’s revenue was up 5.9% compared to the same quarter last year. equities analysts expect that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.
In other news, insider Peter A. Kiener sold 50,000 shares of the business’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the sale, the insider now owns 52,023 shares of the company’s stock, valued at $858,379.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.13% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. grew its position in shares of Sucampo Pharmaceuticals by 36.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 246,796 shares of the biopharmaceutical company’s stock valued at $2,592,000 after buying an additional 66,493 shares during the last quarter. Swiss National Bank raised its holdings in Sucampo Pharmaceuticals by 22.3% in the second quarter. Swiss National Bank now owns 43,859 shares of the biopharmaceutical company’s stock valued at $461,000 after acquiring an additional 8,000 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in Sucampo Pharmaceuticals in the second quarter valued at $117,000. Wells Fargo & Company MN raised its holdings in Sucampo Pharmaceuticals by 11.3% in the second quarter. Wells Fargo & Company MN now owns 65,571 shares of the biopharmaceutical company’s stock valued at $688,000 after acquiring an additional 6,647 shares in the last quarter. Finally, Alliancebernstein L.P. raised its holdings in Sucampo Pharmaceuticals by 30.7% in the second quarter. Alliancebernstein L.P. now owns 38,362 shares of the biopharmaceutical company’s stock valued at $403,000 after acquiring an additional 9,000 shares in the last quarter. 65.16% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Sucampo Pharmaceuticals (SCMP) Lowered to Hold at Zacks Investment Research” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2018/02/09/sucampo-pharmaceuticals-scmp-lowered-to-hold-at-zacks-investment-research.html.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.